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The evidence of a tight spatial interaction
between mast cells (MCs) and B lympho-
cytes in secondary lymphoid organs,
along with the data regarding the abun-
dance of MCs in several B-cell lymphopro-
liferative disorders prompted us to inves-
tigate whether MCs could affect the
proliferation and differentiation of B cells.
To this aim, we performed coculture as-
says using mouse splenic B cells and
bone marrow–derived MCs. Both nonsen-
sitized and activated MCs proved able to
induce a significant inhibition of cell death
and an increase in proliferation of naive B
cells. Such proliferation was further en-
hanced in activated B cells. This effect
relied on cell-cell contact and MC-derived
interleukin-6 (IL-6). Activated MCs could
regulate CD40 surface expression on un-
stimulated B cells and the interaction
between CD40 with CD40 ligand (CD40L)
on MCs, together with MC-derived cyto-
kines, was involved in the differentiation
of B cells into CD138 plasma cells and in
selective immunoglobulin A (IgA) secre-
tion. These data were corroborated by in
vivo evidence of infiltrating MCs in close
contact with IgA-expressing plasma cells
within inflamed tissues. In conclusion, we
reported here a novel role for MCs in
sustaining B-cell expansion and driving
the development of IgA-oriented humoral
immune responses. (Blood. 2010;115(14):
2810-2817)
Introduction
Mast cells (MCs) are the key effector cells in immunoglobulin E
(IgE)–mediated allergic diseases such as atopic asthma, allergic
rhinitis, and atopic dermatitis, but also participate in a variety of
IgE-independent biologic responses.1-4 MCs can produce and
secrete mediators influencing various aspects of the biology of
dendritic cells, T cells, and B cells, thus acting as regulatory
cells.2,4-6 A variety of stimuli can activate MCs; one of the most
efficient is the engagement of receptors for the Fc portion of Ig
(FcR).7,8 MC activation with IgE and specific antigen (Ag) results
in the secretion of a wide spectrum of biologically active mediators
including histamine, serotonin, -hexosaminidase, proteoglycans,
proinflammatory lipid mediators, growth factors, cytokines, and
chemokines. Some of these products can also be released after the
occupancy of MC-FcRI by monomeric IgE antibodies. Engage-
ment of the FcRI initiates activation of several cytoplasmic
protein tyrosine kinases and recruitment of adaptor molecules that
subsequently promote the activation of multiple signaling cas-
cades, including phospholipase C, phosphoinositide-3 kinase,
mitogen-activated protein kinase, and transcription factors.2,9
MCs are dispersed throughout multiple tissues and are located
mainly at the major immunologic interfaces such as skin, gut, and lung.
Secondary lymphoid organs including tonsils and lymph nodes show a
moderate amount of MCs in physiologic conditions, which increases in
the early phases of inflammation, suggesting an active participation of
MCs in the orchestration of the immune response.10
Over the past few years, the association between MCs and
human cancer has progressively emerged and many studies have
highlighted a correlation between the amount of tumor-infiltrating
MCs and the degree of tumor aggressiveness (ie, grade) and
dissemination (ie, stage), which is in favor of a role of MCs in
tumor growth.11 Increased number of MCs have been reported,
among the others, in B-cell neoplasms including Hodgkin lym-
phoma (HL), diffuse large B-cell lymphoma, lymphoplasmacytic
lymphoma, and chronic lymphocytic leukemia.11-16 In this setting,
MCs might play an important role in tumor-associated inflamma-
tion.17 Some studies have demonstrated tumor growth induction
secondary to MC activation,11 and diverse mechanisms including
the release of proangiogenic factors18-20 have been hypoth-
esized.21-23 However, most of these studies investigating the
influence of MCs on the neoplastic clone growth and survival have
focused on solid tumors, and therefore little is known on the role of
MCs in B-cell neoplasms as well as on MC–B-cell interactions.
On this basis, we aimed to investigate the effects of MCs on the
activation and proliferation of B cells by performing coculture
assays using primary mouse B cells purified from spleen and bone
marrow–derived MCs. We showed that MCs promote both survival
and activation of naive B cells as well as proliferation and further
plasma cell differentiation of activated B cells through cell-cell
contact and soluble factors production.
Methods
Human tissue samples
Formalin-fixed, paraffin-embedded bioptic tissue specimens of inflamma-
tory bowel disease, reactive follicular hyperplasia, and chronic lymphocytic
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leukemia were retrospectively gathered from the archives of the Depart-
ment of Human Pathology of the University of Palermo, following the
approval and permission of the Institutional Review Board of the University
Hospital. All the procedures followed were in accordance with the Helsinki
Declaration.
Histopathologic and immunophenotypical analyses on
formalin-fixed paraffin-embedded samples
For immunohistochemical analyses on formalin-fixed and paraffin-
embedded tissue samples, 4-micrometer–thick sections were cut from
paraffin blocks, deparaffinized, and rehydrated to water. Sections under-
went microwave-oven heating for antigen retrieval before endogenous
peroxidase quenching.
Immunohistochemistry was performed using either the streptavidin-
biotin-peroxidase complex (strept-ABC) or the alkaline phosphatase anti–
alkaline phosphatase (APAAP) method as previously reported24 and the
following primary antibodies: mouse anti–human CD20 (clone L26; Dako),
mouse anti–human CD3 (clone LN10; Novocastra), mouse anti–human IgA
(clone N1CLA; Novocastra), and mouse anti–human mast cell tryptase
(clone AA1; Dako). Aminoethylcarbazole (red signal) and 5-bromo,
4-chloro, 3-indolylphosphate/nitro blue tetrazolium chloride (blue signal)
were used as chromogenic substrates.
Double immunohistochemical stainings were performed by 2 consecu-
tive rounds of single immunostaining using strept-ABC and APAAP. Slides
were evaluated by an expert pathologist (C.T.) under a Leica DM3000
optical microscope and microphotographs were collected using a Leica
DFC320 digital camera.
Cell preparation and culture conditions
Murine B cells were isolated from spleen of C57BL/6 mice by a negative
depletion method as previously described,25 and the purity, as percentage of
CD19 cells, was more than 95%. Primary cultures of bone marrow mast
cells were obtained by in vitro differentiation of bone marrow cells taken
from mouse femur as previously described.26 Bone marrow from C57BL/6
IL-6–deficient mice were kindly provided by J. Rivera (National Institutes
of Health). Where indicated, mouse B cells (106 cells/mL) were incubated
with purified anti–mouse CD40 monoclonal antibody (mAb) HM40-3 (BD
Pharmingen) at 1 g/mL and anti–mouse IgM Ab (Jackson ImmunoRe-
search Laboratories) at 0.5 g/mL for the indicated times.25 Before
experiments, 106 cells/mL MCs were sensitized in medium without IL-3 for
at least 4 hours with 1 g/mL dinitrophenol (DNP)–specific IgE, as
previously described.25 When B cells were cultured with MCs, B cells (106
cells/mL) were added to IgE-sensitized or nonsensitized MCs (106 cells/
mL) in the presence or the absence of 100 ng/mL DNP at 37°C for 72 hours
in 96-well, round-bottom plates (Falcon; BD Biosciences).
In some coculture experiments, B cells and MCs were separated by a
transwell polyester membrane using 24-well plates (Costar, Euroclone)
with 0.4-m pore size, following the manufacturer’s recommendations.
Anti–mouse IL-6R (clone 15A7) and anti-CD40L (clone MR1) antibod-
ies were purified from Hybridoma (a gift from M. Colombo, Immuno-
therapy and Gene Therapy Unit, Department of Experimental Oncology,
Istituto Nazionale per lo Studio e la Cura dei Tumori) and used at
50 g/mL. To evaluate the role of CD40L/CD40 signaling pathway in
cocultured studies, the anti-CD40L blocking Ab was added together with
MCs to B cells previously activated with purified anti–mouse CD40 and
anti–mouse IgM Ab for 48 hours at the concentration of 50 g/mL for
48 hours.
Flow cytometric analysis
To assess cell-surface expression of different costimulatory molecules/
activation markers, cells were first washed twice with phosphate-buffered
saline (PBS) and then incubated at 4°C for 30 minutes with fluorescein
isothiocyanate– or phycoerythrin- or biotin-labeled anti–mouse mAbs or
isotype control Ab at 10 g/mL final concentration. For detection of
biotin-conjugated Ab, cells were also incubated with Streptavidin–Cy-
Chrome (BD PharMingen). All Abs were purchased from eBioscience,
except anti–mouse IgA biotin conjugate (BD PharMingen). Anti–mouse
CD40 fluorescein isothiocyanate–conjugated Ab was kindly provided by Dr
Mario Colombo (Istituto Nazionale per lo Studio e la Cura dei Tumori).
Necrotic and apoptotic cells were detected by labeling with annexin V and
propide iodide using annexin V-FLUOS staining kit (Roche Applied
Science) following manufacturer’s instructions. Fluorescence analysis was
accomplished on FACScan (Becton Dickinson) using FlowJo software
(Version 8.5.2; Treestar Inc).
CFSE assays
Freshly purified mouse B cells were labeled with 1 M carboxyfluorescein
succinimidyl ester (CFSE; Molecular Probes) at room temperature for
8 minutes, then washed twice with RPMI 1640 containing 10% fetal calf
serum. After stimulation for 3 days, the CFSE profiles of CD19 B cells
were evaluated by flow cytometry. Cell divisions and proliferation index
were determined using the Proliferation Wizard algorithm ModFit LT
software (Verity Software House). The proliferation Wizard module of
ModFit LT V2.0 indicates the proliferation index as the sum of the cells in
all generations divided by the computed number of original parent cells
present at the start of the experiments, and it is therefore a measure of the
increase in cell number in the culture over the course of the experiment.
Quantification of secreted IgA isotype
Abs produced in cell cultures were detected by enzyme-linked immunosor-
bent assay (ELISA). Briefly, 96-well round-bottom plates polyvinyl plates
(Costar) were coated with affinity-purified anti–mouse isotype-specific
antibody (Southern Biotechnology) at a concentration of 2 g/mL. After
overnight incubation at 4°C, plates were blocked with 3% bovine serum
albumin in PBS for 1 hour at room temperature. Culture supernatants or
standards (100 L; BD PharMingen) diluted in 3% bovine serum albumin–
PBS were added to antibody-coated wells. After overnight incubation at
4°C, plates were washed with 0.05% Tween in PBS, and optimal
concentration of horseradish peroxidase–conjugated goat anti–mouse anti-
body (Southern Biotechnology) was added (for IgA, 1:2000). Plates were
incubated for an additional 1 hour at room temperature and then washed
with PBS, and finally tetramethylbenzidine substrate (Sigma) was added for
20 minutes. Optical density at 405 nm was measured using a Titertek
Multiskan ELISA reader (Labsystems).
Statistical analysis
The 2-tailed Student t test was used to determine the statistical significance
of the data. A P value of less than .05 was considered statistically significant
and indicated with an asterisk.
Results
MCs and B cells display tight spatial interactions in the
T cell–rich area of secondary lymphoid organs
To investigate the actual occurrence of cellular interactions be-
tween MCs and B cells in an inflammatory background, we
performed double immunohistochemical staining for MC tryptase
and the CD20 B-cell marker on tissue sections from lymph nodes
showing reactive follicular hyperplasia. We found numerous MCs
scattered in the paracortical and medullary area of lymph nodes and
surrounding follicles (Figure 1A). MCs intermingled with B cells
and the 2 cell populations clearly showed signs of cell-to-cell
interaction (Figure 1B). Because of the characteristic distribution
of MCs observed, the above-mentioned interactions with B cells
were likely to occur with recirculating naive B cells and acti-
vated post–germinal center B cells in a T cell–rich environment
(Figure 1C).27
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MCs enhance survival and proliferation of naive and activated
B cells
To study whether MCs could influence activation and proliferation
of B cells, we performed coculture assays using murine bone
marrow–derived MCs and splenic B cells.
Proliferation assays were performed by labeling B cells with the
fluorescent dye carboxyfluorescein succinimidyl ester (CFSE) and by
coculturing with MCs. After 72 hours, cells were harvested and
analyzed by flow cytometry. Only CD19 cells in the morphologic gate
were included in the analysis (supplemental Figure 1, available on the
Blood website; see the Supplemental Materials link at the top of the
online article).As shown in Figure 2A, naive B cells (accounting for 6%
of total events) in coculture with nonsensitized MCs progressed through
generations faster than B cells alone, which were programmed to die in
culture in the absence of appropriate signals. Indeed, the total number of
B cells over the fifth generation was 9% ( 1.2%), 39% ( 2.4%), and
57% ( 3.1%) in control and in coculture with nonsensitized and with
IgE-Ag–stimulated MCs, respectively. These data were confirmed by
the cellular proliferation index, which is a measure of the increase in cell
number in the culture over the course of the experiment.28 A significant
increase in the B-cell proliferation index was observed between
nonsensitized and IgE-Ag–activated MCs (Figure 2B). Moreover,
proliferation of CD40- and IgM-activated B cells was substantially
enhanced in the presence of activated MCs (Figure 2C-D). MCs induced
B-cell proliferation, and staining with annexin V and propidium iodide
demonstrated that MCs also promoted B-cell survival, as the percentage
of viable B cells increased whereas that of necrotic cells was reduced in
the coculture system (Table 1). Together, these data suggest that MCs
support the survival and proliferation of primary B cells. No significant
differences were observed in B-cell proliferation between cocultures
using nonsensitized and IgE-sensitized MCs (not shown). Moreover,
decreasing MC/B ratios (1:1, 1:2, and 1:4) were tested, but no significant
differences were measured, suggesting that even low MC concentra-
tions were effective in influencing B-cell survival and proliferation (not
shown).
MC-induced B-cell proliferation requires cell-cell contact and
soluble factors: the role of mast cell–expressed IL-6 and CD40L
Both cell-cell proximity and soluble factors may contribute to
B-cell proliferation enhancement by activated MCs. Thus, we
Figure 1. MCs localize in the paracortical and medullary area of lymph nodes in
close contact with B cells. Double immunohistochemistry for mast cell tryptase and
either CD20 (A-B) or CD3 (C) on lymph node samples with reactive follicular
hyperplasia. (A-B) Mast cells (blue) are localized mainly in the parafollicular zone
extending into the medullary area and showing tight spatial interactions with B cells
(red). (C) In lymph nodes, MCs (blue) are likely to interact also with T cells (red) as the
parafollicular area is rich in T lymphocytes. These pictures are illustrative of the
interactions occurring between MCs and B cells in the context of T cell–rich areas of
lymph nodes (STREPT-ABC and APAAP methods; original magnifications: panels
A,C:100; panel B,200).
Figure 2. MCs promote proliferation of naive B cells and
activated B cells. Naive (B) or activated (Bact) mouse B cells
were labeled with CFSE and cocultured with nonsensitized mast
cells (MCs) or IgE-sensitized MCs stimulated with the antigen
DNP (MC/IgE-Ag). The statistical analyses of CFSE data from
3 independent experiments with naive B cells (A) or activated B
cells (C) are expressed as percentages of cells in each generation
and presented as means SD. P indicates the parent generation.
Proliferation index of naive B cells (B) and activated B cells (D) is
expressed as fold induction over B cells alone, where the
proliferation index average  SD of naive B and activated B cells
alone was fixed to 1 in panels B and D, respectively. Results
shown are the mean of at least 3 separate experiments from
3 different MC cultures. *P  .05.
Table 1. Percentages of viable, necrotic, and apoptotic B cells after
72 hours of coculture
% Cells
Viable Apoptotic Necrotic
B 73.5  2.1 6.5  0.7 20.0  1.4
BMC 82  1.4 12.5  0.7 5.5  0.7
BMC/IgE-Ag 93.5  0.8 3.5  0.1 3.4  0.6
Bact 87.1  0.5 3.8  0.2 9.0  0.7
BactMC 96.7  0.3 1.5  0.1 1.7  0.4
BactMC/IgE-Ag 94.5  0.7 3  0.1 2.5  0.7
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investigated the importance of cell-cell proximity using B cells
cocultured with MCs in the presence of a membrane filter to
separate the 2 cell populations. As shown in Figure 3A and B,
B-cell proliferation was partially reduced when MCs and B cells
were separated. Indeed, 19% ( 1.3%) of naive B cells and 93%
( 0.9%) of activated B cells cocultured with activated MCs
distributed over the fifth generation, compared with 8% ( 0.7%)
and 84% ( 3.2%) of B cells cocultured with activated MCs in the
presence of transwell membranes, supporting the relevance of
cell-cell contact. These data were confirmed by the cellular
proliferation index as detailed in Figure 3C and D.
Activation with IgE-Ag stimulates MCs to express a specific set
of cytokine genes including IL-4, IL-5, IL-6, IL-13, transforming
growth factor- (TGF-), and tumor necrosis factor-, which can
regulate precise events of B-cell physiology.2 In particular, IL-6 is a
key factor influencing B-cell proliferation, maturation, and survival
that has been postulated to play a direct role in the maintenance of
the proliferative spur in B- and plasma cell neoplasms through its
interaction with IL-6R (CD126, CD130) expressed on neoplastic
cells.29-33 On this basis, we decided to use MCs from wild-type
(WT) and IL-6–deficient (IL-6	/	) mice to assess whether MC-
derived IL-6 was required for MC-induced B-cell proliferation. In
MC-naive B-cell (Figure 4A) or MC-activated B-cell (Figure 4B)
cocultures, IL-6 derived from activated MCs proved to be a key
cytokine implicated in B-cell proliferation, because IgE-Ag–
stimulated IL-6	/	 MCs did not enhance B-cell proliferation as
efficiently as WT MCs. Moreover, the B-cell proliferative response
to IgE-Ag–stimulated IL-6	/	 MCs was partially reconstituted by
the addition of recombinant murine IL-6 (data not shown), further
supporting that MC-derived IL-6 strongly sustains B-cell prolifera-
tion. To confirm these data, we repeated coculture experiments
using WT MCs with or without an anti–IL-6R blocking antibody.
Blockade of IL-6R partially inhibited MC-induced proliferation of
naive (Figure 4A) and activated (Figure 4B) B cells, producing a
picture similar to that observed with IL-6	/	 MCs.
Signaling through costimulatory complexes represents the basis
of immune cell activation processes, including that of B cells. In
the model of MC–B-cell interaction we investigated, MCs may act
as accessory cells promoting B-cell activation through the expres-
sion of several costimulatory molecules. To clarify this issue, we
examined MCs for the surface expression of B cell–modulating
molecules by flow cytometry. We and others have demonstrated
that nonsensitized MCs express several costimulatory mol-
ecules,5,6,33,34 including CD40L. In our model, CD40L expression
on MCs was increased by IgE-Ag stimulation, but was not further
enhanced by coculture with B cells (supplemental Figure 2). To
assess whether MCs could promote or enhance the expression of
CD40L-complementary surface molecule CD40 on B cells, CD40
expression on B cells cocultured with MCs was analyzed. We
observed a weak constitutive surface expression of CD40 on naive
B cells, which was significantly increased by coculture with
IgE-Ag–activated MCs (Figure 4C). By contrast, only a slight
increase of CD40 expression was observed on activated B cells in
the presence of MCs (Figure 4C). Moreover, blockade of CD40L
on MCs produced a partial, although significant, inhibition of
MC-induced proliferation of activated B cells (Figure 4D and
supplemental Figure 3), but did not influence naive B-cell prolifera-
tion (not shown). Thus, neither cell-cell contact alone nor the mere
release of a soluble mediator was responsible for the whole effect
of MCs on B-cell proliferation, but both of these mechanisms
contributed to the final effect.
Plasma cell differentiation and IgA isotype secretion are the
end products of MC–B-cell interactions
Because proliferation of B cells is regarded as a prerequisite for the
progression toward Ig-secreting plasma cells,35 IL-6 is active in
inducing B-cell differentiation,36 and CD40/CD40L axis has a
major role in promoting isotype switching,37 we decided to
investigate whether MCs were able to sustain differentiation of
mature activated B cells into Ig-producing plasma cells. To this
aim, we first analyzed the expression of the CD138 plasma cell
marker on the surface of B cells upon coculture with MCs. As
shown in Figure 5, CD138 expression on gated CD19 cells was
increased in naive B cells cocultured with MCs, independently of
the MC activation status. Activation of B cells enhanced the
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Figure 3. The enhancement of B-cell proliferation by MCs requires
cell-cell contact and soluble factors. Naive or activated B cells were
labeled with CFSE and cocultured for 72 hours with activated MCs
separated or not by a transwell membrane. The statistical analyses of
CFSE data of B cells in contact (A) or separated (C) by a transwell (TW)
are expressed as percentages of cells in each generation and presented
as means  SD of 3 separate experiments from 2 different MC cultures.
Open and black histograms represent the percentage of naive (B) and
activated (Bact) B cells in each generation, respectively; P indicates the
parent generation. Results of proliferation index are expressed as fold
induction over B cells alone, where the proliferation index average  SD
of naive B and activated B cells alone was fixed to 1 in panels B and D,
respectively. *P  .05.
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expression level of CD138, which was not influenced by MC
presence in the coculture, as indicated by unchanged MIF values
(Figure 5B).
Subsequently, the expression of immunoglobulin molecules
was evaluated on naive and activated B cells in the presence of
MCs. No significant differences in IgG, IgM, and IgD surface
expression were detected between activated B cells alone or in
coculture with unstimulated and activated MCs (data not shown),
whereas only a slight increase in surface IgE expression was
observed on B cells activated in the presence of IgE-Ag–stimulated
MCs (supplemental Figure 4A). Instead, IgA expression was
selectively increased on activated B cells cocultured with IgE-Ag–
activated MCs, suggesting that in the presence of MCs B cells
successfully underwent isotype switching (Figure 6A and supple-
mental Figure 4B). The increase of IgA surface expression on B
cells induced by coculture with MCs was prevented using IL-6–
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Figure 5. MCs induce increase of CD138 expression on naive
B cells. Surface expression of CD138 on B cells was analyzed by
flow cytometry after 72 hours of B-cell and MC cocultures in the
same condition of Figure 2. (A) Histograms of cell numbers on the
y-axis plotted against log fluorescence intensity of CD138 on
x-axis. A representative histogram is shown here of 2 independent
experiments. Filled histograms (left, gray) indicate isotype control
antibody. (B) The mean fluorescence intensity (MFI) of CD138
expression on naive B cells (B) and on activated B cells (Bact) at
baseline and in coculture with nonsensitized MCs (MC) or acti-
vated MCs (MC/IgE-Ag) is shown. Results shown are representa-
tive of at least 2 independent experiments.
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Figure 4. MC-derived IL-6 and CD40-CD40L interactions are
involved in B-cell proliferation up-regulation. Naive (B) or
activated B cells (Bact) were labeled with CFSE and cocultured
as indicated. Proliferation index of naive B (A) and activated
B cells (B) cultured alone, with nonsensitized MCs (MC), with
activated MCs (MC/IgE-Ag), and with activated IL-6	/	 MCs and
in the presence of anti–IL-6R or isotype control antibody (Ctrl)
were analyzed by flow cytometry. Proliferation indexes are from
3 independent experiments with naive B cells and activated
B cells, respectively. Proliferation indexes from naive B and
activated B cells alone were fixed to 1. *P  .05. Date are the
average  SD (C) The mean fluorescence intensity of CD40
expression on naive B cells (B) and on activated B cells (Bact) at
baseline and in coculture with nonsensitized MCs (MC) or
activated MCs (MC/IgE-Ag) is shown. (D) Proliferation indexes of
activated B cells alone, cocultured with activated MCs without and
with blocking CD40LAb or control Ab, are calculated. Proliferation
index of activated B cells alone was fixed to 1. Results are from
3 independent experiments using at least 3 different cultures of
MCs. *P  .05; ** P  .02.
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deficient MCs and blocking IL-6R or CD40/CD40L interaction
(Figure 6A and supplemental Figure 4B).
Because activated B cells are a potential source of IL-6, we
wanted to rule out the possibility of a contribution of endoge-
nous IL-6 to the activated B-cell plasmacytic differentiation we
observed in coculture experiments. At the same time, we studied
the production of 2 other key promoters of B-cell plasmacytic
differentiation, namely IL-5 and TGF-.38,39 IL-6, IL-5, and
TGF- levels were assessed in the supernatants of MC–B-cell
cocultures. In contrast to a previous report,40 B-cell activation
through anti-CD40 and anti-IgM Ab cross-linking did not result
in IL-6 production (supplemental Figure 5A), and the only
source of IL-6 in the coculture proved to be sensitized MCs.
IL-5 and TGF- levels (supplemental Figure 5B-C) were
exclusively detected upon MC activation, supporting the central
role of MCs in the B-cell differentiation toward IgA-producing
plasma cells.
Finally, to further confirm the actual differentiation of B cells
into Ig-secreting plasma cells, the supernatants of MC–B-cell
cocultures were harvested and analyzed for IgA content by ELISA.
Activated B cells cocultured with activated MCs secreted consider-
able amounts of IgA, and this production was significantly limited
by IL-6R or CD40L blockade (Figure 6B).
In vivo evidence of concomitant accumulation of MCs and
IgA-secreting plasma cells at sites of tissue inflammation
MCs are known to accumulate at sites of inflammation in the
colonic mucosa of patients with inflammatory bowel disease.41
However, their role in the pathogenesis of these disorders, as well
as their exact contribution to the composition of the inflammatory
infiltrate, is largely obscure.
We assessed the distribution of MCs in bioptic samples of
inflammatory bowel disease (ulcerative colitis, Crohn disease,
nonspecific colitis) patients and found that MCs preferentially
accumulated in the lamina propria, where they colocalized with
CD20 B cells (Figure 7A) and associated with abundant IgA
secretion (Figure 7B).
IgA class switch is a characteristic feature of lymphocytes
populating the mucosa-associated lymphoid tissue,42 and its
occurrence in peripheral lymph nodes is a rare event. Neverthe-
less, lymph nodes with reactive follicular hyperplasia com-
monly show low numbers of IgA-secreting plasma cells scat-
tered among more abundant IgG plasma cells (Figure 7C).
Interestingly, we found that these few IgA-expressing plasma
cells selectively occurred in areas populated by MCs, where
the 2 cell populations displayed tight spatial interactions
(Figure 7D inset).
Figure 7. Colocalization between MCs and IgA-secreted plasma cell in inflamed
mucosal tissue. (A-B) In the gut mucosa of patients with inflammatory bowel
disease, MCs (A-B blue signal) accumulate at sites of inflammation where they
colocalize with CD20-expressing B cells (A red signal) and IgA-secreting plasma cells
(B, red signal). (C-D) In lymph nodes with reactive follicular hyperplasia, in which IgG
class switch is prominent, the distribution of IgG-expressing plasma cells (C red
signal) appears to be unrelated to that of MCs (C-D blue signal). By contrast, the few
IgA-expressing plasma cells (D red signal) localize mainly in close proximity of MCs
and even show signs of cell-cell contact (inset). (STREPT-ABC and APAAP methods;
original magnifications: panels A-B,200; panels B-C,100; inset,400.)
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Figure 6. MC-derived IL-6 and CD40L-CD40 signaling induces IgA surface
expression and secretion by activated B cells. Analysis of surface IgA by activated
B cells in presence of cultured activated MCs. (A) MIFs of IgA surface expression on
activated B cells cultured alone or with activated WT MCs and with IL-6	/	 MCs and in
the presence of anti–IL-6R or anti-CD40L antibody are measured by flow cytometry.
IgA surface expression on B cells alone with anti–IL-6R and of anti-CD40L isotype
control antibody was also analyzed by flow cytometry (Ctrl). (B) Secreted IgA by
activated B cells cultured alone, with activated WT MCs and with IL-6	/	 MCs and in
the presence of anti–IL-6R or control antibody (Ctrl), and in the presence of
anti-CD40L antibody or control antibody (Ctrl), was detected by ELISA. The results
are the average SD of values from 3 separate experiments using at least 3 different
cultures of MCs. *P  .05; **P  .001.
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Taken together these pictures are suggestive of an interplay
between MCs, B cells, and IgA-secreting plasma cells that takes
place in vivo in an inflammatory background.
Discussion
The major compelling element strengthening the need for a deep
understanding of MC–B-cell interactions is the long-standing
evidence of the association between MCs and B-cell lymphoma-
tous aggregates, which was originally described by Lennert’s group
in 1977 (Satodate et al).43 Since then, many other reports have
focused on the abundance of MCs at sites of leukemic/lymphoma-
tous infiltration, especially in mature indolent B-cell neoplasms
such as chronic lymphocytic leukemia and lymphoplasmacytic
lymphoma (Waldenstro¨m macroglobulinemia).11-16 In these condi-
tions, MCs can be found surrounding neoplastic lymphoid aggre-
gates (supplemental Figure 6A) or even intermingling with neoplas-
tic cells (supplemental Figure 6B), suggesting an active participation
of MCs to the composition of the lymphoma-associated microenvi-
ronment. In this regard, a direct contribution of neoplastic cells to
the recruitment of MCs at sites of infiltration via CCL5 synthesis
has been demonstrated in Hodgkin lymphoma (HL).44 The hypoth-
esis that MCs have an influence on neoplastic B cells is corrobo-
rated by retrospective studies reporting the prognostic significance
of MCs in B-cell lymphoproliferative disorders.15,45 The majority
of these reports put into evidence a detrimental role of MCs in the
prognosis of HL disease and B-cell non-Hodgkin lymphoma
lymphomas, but contrasting evidence of the association of MCs
with a favorable prognosis in some specific subtypes of B-cell
non-Hodgkin lymphoma (ie, diffuse large B-cell lymphoma) has
also been reported.12 Altogether, these data provided an overview
on the complexity of the role of MCs in B-cell lymphoproliferative
diseases, as MCs may be able to directly interact with neoplastic B
cells, influencing their growth and survival, or to shape the
tumor-associated stromal and inflammatory microenvironment. In
keeping with the first hypothesis are data demonstrating that
MCs can activate Hodgkin lymphoma Reed-Sternberg cells
through CD30L/CD30 interaction, probably leading to an in-
creased proliferation of Hodgkin lymphoma Reed-Sternberg cells.15
Moreover, in lymphoplasmacytic lymphoma, MCs have been
reported to support neoplastic cell proliferation and survival
through CD40/CD40L or CD27/CD70 interactions.13,16 On the
other hand, MCs as well-known sources of proinflammatory and
proangiogenic mediators have been described in association with
an inflammatory cell–rich background and increased angiogenesis
in HL.46
Finally, data on the possible link between MCs and B
lymphocytes come also from the reported spatial association
between the neoplastic MC aggregates of indolent systemic
mastocytosis and surrounding B-cell lymphoid aggregates, as
well as from few detailed reports on the concurrence of systemic
mastocytosis and chronic lymphocytic leukemia that allow for
speculation on the role of MCs in B-cell recruitment, activation,
and proliferation.14
In the present study, we have uncovered a specific role of MCs
in B-cell growth and differentiation. We reported that mouse bone
marrow–derived MCs can induce both survival and proliferation of
primary naive B cells and proliferation and further differentiation
of activated B cells into IgA-secreting plasma cells.
B-cell proliferation was reduced when MCs and B cells were
separated by the transwell membranes or when MCs were IL-6
deficient, suggesting that soluble factors and cell-cell contact are
important in this event.
Interestingly, analyzing the immunophenotype of MCs and B
cells in the coculture, we reported evidence that MCs can
influence the surface expression of CD40 on naive B cells,
suggesting that MCs activated by IgE and Ag are fully capable
of enhancing B-cell activation. Indeed, it is known that B-cell
activation results in enhanced CD40 expression47,48 and that the
interaction of this molecule with its receptor on MCs results in
costimulatory signals leading to the productive survival, activa-
tion, and expansion of B cells. Moreover, we demonstrated that
the interaction of CD40 on B-cell surface and CD40L on MCs is
important for the proliferation of B cells and for their differentia-
tion into plasma cells.
We showed for the first time that activated MCs are able to
induce IgA surface expression on activated B cells and IgA
secretion. Hence, we suggested a new role of MCs in the induction
of humoral immune responses, which is likely to occur through the
release of cytokines, such as IL-5, IL-6, TGF-, and others. Indeed,
it is known that IL-6 is an efficient cofactor of IL-5 in IgA
synthesis36 and TGF- is a costimulator for IgA production.49
Accordingly, our findings might contribute to clarify the mecha-
nisms underlying defective IgA-mediated humoral immune re-
sponses to specific pathogens (eg, Giardia lamblia) that can be
observed in Kitw/wv mice lacking mast cells.50
Taken together our data significantly expand the paradigm of
MCs as key players in the orchestration of the immune response, as
they add a valuable piece to the mosaic of functions that innate
immune cells endorse in adaptive immunity. Moreover, they cast
new light on the dynamics possibly underlying MC involvement in
B-cell homeostasis and in B-cell lymphoproliferative disorders. In
this setting, we suggest that MCs could have a share in directly
sustaining the expansion of the B-cell clone through IL-6 produc-
tion and cell-cell interaction.
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